Colorectal Cancer Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Exelixis, Mirati Therapeutics, Merck Sharp & Dohme LLC, Daiichi Sankyo Company, Inspirna, Lyell Im

Colorectal Cancer Pipeline constitutes 195+ key companies continuously working towards developing 200+ Colorectal Cancer treatment therapies, analyzes DelveInsight.

Colorectal Cancer Overview:

Colorectal cancer (CRC) is a condition that affects the colon, caused by abnormal growth of glandular epithelial cells in the colon. It can be classified into three main types: sporadic, hereditary, and colitis-associated. The incidence of CRC is rising globally, influenced by both environmental and genetic factors. Patients with long-standing ulcerative colitis or Crohn's disease are at a higher risk of developing CRC, and this risk increases with age. Studies have shown that factors such as diet, lifestyle, family history, and chronic inflammation play significant roles in the development of CRC.

CRC is a multifactorial disease, with the epithelial cells in the colorectal mucosa undergoing various stages, from hyperplasia and atypical hyperplasia (mild to severe) to adenomas, which can eventually progress to carcinoma. This transformation is typically initiated by carcinogenic factors that cause DNA damage, leading to the malignant change of cells into cancer. The process involves morphological changes, including epithelial hyperplasia, adenoma formation, carcinoma in situ, and invasive carcinoma. In 1990, Fearon and Vogelstein proposed a model explaining the molecular events behind CRC's development. Further research has identified three key molecular mechanisms involved in CRC: (i) chromosomal instability, often seen in familial adenomatous polyposis (FAP), (ii) genetic mutations like those in Lynch syndrome and other sporadic MMR mutations, and (iii) hypermethylation of CpG islands in gene promoters. These processes are linked to abnormal changes in genes such as APC, DCC, P53, K-ras, c-MYC, MCC, and MMR-related genes (e.g., hMLH1, hMLH3, hMSH2, hMSH3, hMSH6, hPMS1, and hPMS2). It's important to note that these molecular alterations are not mutually exclusive, and many CRC patients exhibit multiple abnormal molecular pathways.

Request for a detailed insights report on Colorectal Cancer pipeline insights @ https://www.delveinsight.com/report-store/colorectal-cancer-crc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Colorectal Cancer Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Colorectal Cancer Therapeutics Market.

Key Takeaways from the Colorectal Cancer Pipeline Report

DelveInsight's Colorectal Cancer pipeline report depicts a robust space with 195+ active players working to develop 200+ pipeline therapies for Colorectal Cancer treatment.
In October 2024, U.S. regulators extended the evaluation period for Amgen's LUMAKRAS (sotorasib) for second-line colorectal cancer (CRC) by three months, delaying a potential approval decision until January 17 of the following year. This extension also temporarily reduces the competitive pressure on Bristol Myers Squibb's KRAS inhibitor, KRAZATI (adagrasib).
In June 2024, Bristol Myers Squibb announced that the US FDA granted accelerated approval for KRAZATI (adagrasib) in combination with cetuximab for adult patients with previously treated kras G12C-mutated locally advanced or metastatic colorectal cancer.
In April 2024, ENHERTU was approved in the US as the first tumor-agnostic HER2-directed therapy for patients with metastatic HER2-positive solid tumors, including colorectal cancer, who had been previously treated.
In November 2023, the US FDA approved Takeda's FRUZAQLA for adults with metastatic colorectal cancer who had previously received specific chemotherapies and targeted therapies.
Key Colorectal Cancer companies such as Exelixis, Mirati Therapeutics, Merck Sharp & Dohme LLC, Daiichi Sankyo Company, Inspirna, Lyell Immunopharma, Genentech, Cantargia AB, Arcus Biosciences, Inc, Neogap Therapeutics AB, Criterium, Inc, Daiichi Sankyo, Inc, Bristol-Myers Squibb, Celyad Oncology SA, Pfizer, Akeso, Menarini Group, Elpiscience (Suzhou) Biopharma, Ltd., BeyondBio Inc., Shanghai Henlius Biotech, Rottapharm Biotech, Innovative Cellular Therapeutics Inc., BioNTech SE, and others are evaluating new drugs for Colorectal Cancer to improve the treatment landscape.
Promising Colorectal Cancer pipeline therapies in various stages of development include XL092, Adagrasb, Olaparib, DS-8201, Ompenaclid, LYL845, RG6286, and others.

Colorectal Cancer Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Colorectal Cancer Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Colorectal Cancer treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Colorectal Cancer market.

Download our free sample page report on Colorectal Cancer pipeline insights @ https://www.delveinsight.com/sample-request/colorectal-cancer-crc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Colorectal Cancer Emerging Drugs

XL092 : Exelixis
Adagrasb : Mirati Therapeutics
Olaparib : Merck Sharp & Dohme LLC/Astrazeneca
DS-8201: Daiichi Sankyo
Ompenaclid: Inspirna
LYL845: Lyell Immunopharma
RG6286: Genentech

Colorectal Cancer Companies

There are over 195 key companies working on developing therapies for Colorectal Cancer. Among them, Exelixis has drug candidates for Colorectal Cancer in the most advanced stage, Phase III.

DelveInsight's report covers around 200+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Colorectal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Colorectal Cancer Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Colorectal Cancer Therapies and Key Companies: Colorectal Cancer Clinical Trials and advancements @ https://www.delveinsight.com/report-store/colorectal-cancer-crc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Colorectal Cancer Pipeline Therapeutic Assessment
• Colorectal Cancer Assessment by Product Type
• Colorectal Cancer By Stage
• Colorectal Cancer Assessment by Route of Administration
• Colorectal Cancer Assessment by Molecule Type

Download Colorectal Cancer Sample report to know in detail about the Colorectal Cancer treatment market @ Colorectal Cancer Therapeutic Assessment @ https://www.delveinsight.com/sample-request/colorectal-cancer-crc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Colorectal Cancer Current Treatment Patterns
4. Colorectal Cancer - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Colorectal Cancer Late-Stage Products (Phase-III)
7. Colorectal Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Colorectal Cancer Discontinued Products
13. Colorectal Cancer Product Profiles
14. Colorectal Cancer Key Companies
15. Colorectal Cancer Key Products
16. Dormant and Discontinued Products
17. Colorectal Cancer Unmet Needs
18. Colorectal Cancer Future Perspectives
19. Colorectal Cancer Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Colorectal Cancer Pipeline Reports Offerings: https://www.delveinsight.com/report-store/colorectal-cancer-crc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.